- Encompass Health Corp. has announced plans to build a freestanding, 40-bed inpatient rehabilitation hospital in Bear, Delaware, expanding its network and adding its second location in the state to serve patients with complex neurological, orthopedic and other debilitating conditions.
- The facility’s focus on advanced rehabilitation technologies, specialized clinical teams and comprehensive in-house services such as dialysis underlines Encompass Health’s emphasis on higher-acuity, medically complex care within its growing national footprint.
- We’ll now examine how this planned 40-bed Bear, Delaware hospital could influence Encompass Health’s broader investment narrative and growth framework.
We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Encompass Health Investment Narrative Recap
To own Encompass Health, you need to be comfortable with a capital intensive, bed expansion model in inpatient rehab and its exposure to labor and reimbursement risk. The planned 40 bed Bear, Delaware hospital fits the existing de novo growth playbook and does not meaningfully change the near term catalyst of new capacity ramping, nor the key risks around staffing availability and returns on these build outs.
The Bear announcement sits alongside a busy build pipeline, including the recently opened Encompass Health Rehabilitation Hospital of Irmo in South Carolina, which already adds new beds to the network. Together, these projects highlight how much of the company’s story depends on converting new facilities into profitable volumes without letting construction, ramp up and labor costs erode margins.
But investors should also be aware that if labor shortages persist and wage pressures intensify in new hospitals, then …
Read the full narrative on Encompass Health (it's free!)
Encompass Health's narrative projects $7.2 billion revenue and $711.6 million earnings by 2028. This requires 8.1% yearly revenue growth and about a $189.2 million earnings increase from $522.4 million today.
Uncover how Encompass Health's forecasts yield a $142.73 fair value, a 44% upside to its current price.
Exploring Other Perspectives
Four fair value estimates from the Simply Wall St Community span roughly US$99 to US$154 per share, showing wide variation in expectations. Against that backdrop, the company’s ongoing push to open and ramp new hospitals puts execution risk and capital efficiency at the center of its future performance, so it is worth weighing several viewpoints before deciding how you see Encompass Health’s path.
Explore 4 other fair value estimates on Encompass Health - why the stock might be worth as much as 56% more than the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Encompass Health research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Encompass Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Encompass Health's overall financial health at a glance.
Contemplating Other Strategies?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Uncover the next big thing with 29 elite penny stocks that balance risk and reward.
- AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com